MediPharm Labs Corp. Reports Strong Q3 2026 Financial Performance
MediPharm Labs Corp. (TSX: LABS) announced its financial results for the three months ended September 30, 2026, reflecting continued growth and profitability in the pharmaceutical cannabis sector.
Revenue Growth
- Q3 Revenue: $11.8 million, an 18 % increase from the $9.984 million reported for Q2 2026.
- Year‑to‑date revenue (nine months): $30.6 million, up 31 % versus the same period in 2025.
- More than 80 % of revenue comes from prescription‑based medical channels, and 55 % of sales are generated internationally.
Profitability Metrics
- Gross profit: $3.806 million, a 27 % rise from $3.322 million in Q3 2025.
- Gross margin: 32 %, compared with 26 % in Q3 2025.
- Adjusted EBITDA: $0.442 million for Q3, improving by $1.5 million relative to Q3 2025.
- Net income: $112 k, the second consecutive quarter of positive net income.
Operating Efficiency
- Operating expenses: $3.585 million, 25 % lower than Q3 2025 and 11 % lower than Q2 2026.
- Cash position: $10.1 million at quarter‑end, up from $9.9 million in Q2 2026.
Strategic Initiatives
MediPharm Labs has expanded its international footprint, notably with the commercial launch of an ANVISA‑authorized cannabis extract oil in Brazil. The product is now available through the Brazilian pharmacy network, marking a significant milestone in the company’s global expansion strategy.
Outlook and Guidance
CEO Greg Hunter emphasized that the company is building a stronger, more profitable business, with a differentiated regulatory and manufacturing platform driving international growth. The company remains virtually debt‑free and owns two production facilities appraised at over $15 million.
MediPharm Labs will host a conference call and webcast on November 12, 2026, at 10:00 am ET to discuss the results in detail.
